Your account is not claimed yet. You can sign up with ORCID to claim your account.

De-Ke Jiang

ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 12

Top Venues

Alimentary pharmacology & therapeutics

Journal of clinical and translational hepatology

Liver international : official journal of the International Association for the Study of the Liver

Molecular carcinogenesis

Nanfang Hospital, Southern Medical University

Fudan University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Nanfang Hospital, Southern Medical University Jan 1o 2017

China

Professor :: Department of Infectious Diseases and Hepatology Unit

Education History

Fudan University Sep 1o 2004 - Jun 30o 2008

China

PHD :: School of Life Sciences

Publications

Mengqi Luo, Lingyan Zhang, Chou Yang, Bin Zhou, Jinlin Hou, De-Ke Jiang
CXCL13 variant predicts pegylated-interferon α treatment response in HBeAg-positive chronic hepatitis B patients. Journal of medical virology 95 (7) (2023)
Shuang Lou, Jialin Wang, Jiaxuan Chen, Haisheng Xie, Haitao Chen, Bin Zhou, Bo Zhang, Jinlin Hou, De-Ke Jiang
The Role of ALPK1 in Inhibiting HBV Replication Facilitates the Identification of ALPK1 P660L Variant for Predicting PegIFNα Therapy Response. The Journal of infectious diseases (2023)
Shanfeng Li, Jialin Wang, Haitao Chen, Jia Hou, Ting Shen, Jing Li, Bin Zhou, Bo Zhang, Hui Liu, De-Ke Jiang
TRIM16 E121D variant affects the risk and prognosis of hepatocellular carcinoma by modulating the Wnt/β-catenin pathway. Molecular carcinogenesis (2023)
Jiaxuan Chen, Shuang Lou, Haitao Chen, Bin Zhou, Jian Sun, Jinlin Hou, De-Ke Jiang
CD55 Variant Associated with Pegylated-interferon α Therapy Response in HBeAg-positive Chronic Hepatitis B Patients. Journal of clinical and translational hepatology 11 (2) (2022)
Jiaxuan Chen, Haitao Chen, Haoming Mai, Shuang Lou, Mengqi Luo, Haisheng Xie, Bin Zhou, Jinlin Hou, De-Ke Jiang
A functional variant of CD40 modulates clearance of hepatitis B virus in hepatocytes via regulation of the ANXA2/CD40/BST2 axis. Human molecular genetics (2022)
Mengqi Luo, Jia Hou, Haoming Mai, Jiaxuan Chen, Haitao Chen, Bin Zhou, Jinlin Hou, De-Ke Jiang
TRIM26 inhibits hepatitis B virus replication by promoting HBx degradation and TRIM26 genetic polymorphism predicts PegIFNα treatment response of HBeAg-positive chronic hepatitis B Patients. Alimentary pharmacology & therapeutics 56 (5) (2022)
Ting Shen, Ting Ni, Jiaxuan Chen, Haitao Chen, Xiaopin Ma, Guangwen Cao, Tianzhi Wu, Haisheng Xie, Bin Zhou, Gang Wei, Hexige Saiyin, Suqin Shen, Peng Yu, Qianyi Xiao, Hui Liu, Yuzheng Gao, Xidai Long, Jianhua Yin, Yanfang Guo, Jiaxue Wu, Gong-Hong Wei, Jinlin Hou, De-Ke Jiang
An enhancer variant at 16q22.1 predisposes to hepatocellular carcinoma via regulating PRMT7 expression. Nature communications 13 (1) (2022)
Haoming Mai, Haisheng Xie, Mengqi Luo, Jia Hou, Jiaxuan Chen, Jinlin Hou, De-Ke Jiang
Implications of Stemness Features in 1059 Hepatocellular Carcinoma Patients from Five Cohorts: Prognosis, Treatment Response, and Identification of Potential Compounds. Cancers 14 (3) (2022)
Mengqi Luo, De-Ke Jiang
Editorial: tripartite motif 26 inhibits hepatitis B virus replication and its genetic polymorphism predicts response to interferon treatment-towards a better understanding of interferon responsiveness in chronic hepatitis B. Authors' reply. Alimentary pharmacology & therapeutics 56 (6) (2022)
Jiaxuan Chen, Shuang Lou, Haitao Chen, Bin Zhou, Jian Sun, Jinlin Hou, De-Ke Jiang
CD55 Variant Associated with Pegylated-interferon α Therapy Response in HBeAg-positive Chronic Hepatitis B Patients. Journal of clinical and translational hepatology 11 (2) (2022)
Ting Shen, Shan-Feng Li, Jia-Lin Wang, Ting Zhang, Song Zhang, Hai-Tao Chen, Qian-Yi Xiao, Wei-Hua Ren, Chao Liu, Bo Peng, Xiao-Na Ji, Yang Yang, Pei-Xin Lu, Tao-Yang Chen, Long Yu, Yuan Ji, De-Ke Jiang
TP53 R249S mutation detected in circulating tumour DNA is associated with Prognosis of hepatocellular carcinoma patients with or without hepatectomy. Liver international : official journal of the International Association for the Study of the Liver 40 (11) (2020)
Haitao Chen, Jian Sun, Bin Zhou, Jinxin Peng, Qing Xie, Xieer Liang, Rong Fan, Carly Conran, Jianfeng Xu, Yuan Ji, Xinxin Zhang, Li Sun, Ji-Dong Jia, Guiqiang Wang, Jinlin Hou, De-Ke Jiang
A missense variant in complement factor B (CFB) is a potential predictor of 24-week off-treatment response to PegIFNα therapy in Chinese HBeAg-positive chronic hepatitis B patients. Alimentary pharmacology & therapeutics 51 (4) (2020)

De-Ke Jiang.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

De-Ke Jiang